What immunosuppressive medication is used after a renal (kidney) transplant?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: February 23, 2025 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Ask Question

From the Guidelines

After a kidney transplant, patients should be prescribed a combination of immunosuppressant medications, including a calcineurin inhibitor (such as tacrolimus), an antiproliferative agent (like mycophenolate), and corticosteroids (usually prednisone), as recommended by the KDIGO clinical practice guideline 1. The standard regimen usually includes these medications started immediately after transplantation and continued long-term, often for the rest of the patient's life, though dosages may be adjusted over time.

  • The choice of calcineurin inhibitor, either tacrolimus or cyclosporine, is crucial, with tacrolimus being the first-line CNI used 1.
  • The antiproliferative agent, such as mycophenolate, is also an essential component of the immunosuppressive regimen, with mycophenolate being the first-line antiproliferative agent 1.
  • Additionally, patients may receive antibiotics, antiviral medications, and antifungal drugs to prevent infections while their immune system is suppressed, such as trimethoprim-sulfamethoxazole for pneumocystis pneumonia prevention and valganciclovir for cytomegalovirus prophylaxis. The exact combination and dosage of medications will be tailored to each individual patient based on their specific needs and risk factors, including the risk of developing new-onset diabetes, which is higher with tacrolimus compared to cyclosporine 2. Regular blood tests are necessary to monitor drug levels and adjust dosages accordingly, with the goal of using the lowest planned doses of maintenance immunosuppressive medications by 2–4 months after transplantation, if there has been no acute rejection 1. It's crucial for transplant recipients to adhere strictly to their medication regimen to ensure the long-term success of the transplant and prevent rejection of the new kidney.

From the FDA Drug Label

14 CLINICAL STUDIES 14. 1 Kidney Transplantation

Tacrolimus / Azathioprine (AZA) Tacrolimus-based immunosuppression in conjunction with azathioprine and corticosteroids following kidney transplantation was assessed in a randomized, multicenter, non-blinded, prospective trial. Tacrolimus/Mycophenolate Mofetil (MMF) Tacrolimus-based immunosuppression in conjunction with MMF, corticosteroids, and induction has been studied

The immunosuppressive medication used after a renal (kidney) transplant is tacrolimus, often in combination with other medications such as azathioprine or mycophenolate mofetil and corticosteroids 3.

  • Key points:
    • Tacrolimus is used in conjunction with other immunosuppressive medications.
    • The combination of tacrolimus with azathioprine or mycophenolate mofetil and corticosteroids has been studied in clinical trials.
    • These combinations have shown effectiveness in preventing rejection and promoting graft survival in kidney transplant patients.

From the Research

Immunosuppressive Medications Used After Renal Transplant

The following immunosuppressive medications are commonly used after a renal transplant:

  • Tacrolimus 4, 5, 6, 7, 8
  • Mycophenolate mofetil (MMF) 4, 5, 6, 7, 8
  • Corticosteroids (such as prednisone) 4, 5, 8
  • Everolimus 7
  • Basiliximab 6
  • Cyclosporine 4
  • Mizoribine 4

Combination Therapies

Combination therapies are often used to minimize the risk of rejection and reduce the dosage of individual medications:

  • Tacrolimus and MMF 5, 6, 8
  • Tacrolimus and everolimus 7
  • Tacrolimus, MMF, and corticosteroids 5, 8
  • Cyclosporine, MMF or mizoribine, and corticosteroids 4

Dosage and Administration

The dosage and administration of these medications can vary depending on the individual patient's needs and the specific transplant protocol:

  • Low-dose steroid maintenance therapy has been shown to be safe and effective 4
  • Extended-release tacrolimus can be administered once daily 6
  • The dosage of MMF can be adjusted based on the patient's renal function and other factors 5, 6

References

8
Research

Current immunosuppressive treatment after kidney transplantation.

Expert opinion on pharmacotherapy, 2011

Related Questions

What is the initial immunosuppressive regimen for kidney transplant patients?
What are the goals for a patient 4 years after a kidney transplant (Kidney Transplantation)?
What are the renal effects of tacrolimus (immunosuppressant) and how are they managed?
What are the safe doses of prednisone and famotidine (Pepcid) for an adult stable kidney‑transplant recipient?
What dose of corticosteroids (steroids) is recommended for patients with kidney transplant (renal graft) rejection syndrome, also known as acute rejection or graft intolerance syndrome?
What is the differential diagnosis (Ddx) for lower extremity swelling?
What can be done to alleviate constipation likely caused by pudendal neuralgia, given that prune juice, coffee, and fiber supplements have had a limited impact?
In a patient with pyelonephritis (inflammation of the kidney), which type of urinary cast is more likely to be present: fatty, hyaline, muddy brown, red blood cell (RBC), or white blood cell (WBC)?
What is the procedure for a renal (kidney) transplant?
What complication from Roux-en-Y gastric bypass surgery causes immediate postprandial (after eating) episodes of sweaty and non-bloody diarrhea that resolve spontaneously within two hours?
What is the cause of blue swollen feet, also known as cyanotic (cyanosis) edema (fluid retention)?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.